NO20090256L - Modulatorer for kjemokine reseptoraktivitet, krystallinske former og prosesser - Google Patents

Modulatorer for kjemokine reseptoraktivitet, krystallinske former og prosesser

Info

Publication number: NO20090256L
Authority: NO; Norway
Prior art keywords: present; crystalline forms; receptor activity; modulators; processes
Prior art date: 2006-07-28

Application number

NO20090256A

Other languages

English (en)

Norwegian (no)

Inventor

Jale Muslehiddinoglu

Zili Xiao

Michael G Yang

Robert J Cherney

Martin Eastgate

Siva Josyula Prasad

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-28

Filing date

2009-01-16

Publication date

2009-02-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38823540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090256(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-16 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2009-02-25 Publication of NO20090256L publication Critical patent/NO20090256L/no

Links

238000000034 method Methods 0.000 title abstract 3
230000000694 effects Effects 0.000 title abstract 2
102000009410 Chemokine receptor Human genes 0.000 title 1
108050000299 Chemokine receptor Proteins 0.000 title 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
239000005557 antagonist Substances 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
102000004497 CCR2 Receptors Human genes 0.000 abstract 1
108010017312 CCR2 Receptors Proteins 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
230000001363 autoimmune Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
-1 isopropyl (methyl) amino Chemical group 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 abstract 1
239000004031 partial agonist Substances 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)

NO20090256A 2006-07-28 2009-01-16 Modulatorer for kjemokine reseptoraktivitet, krystallinske former og prosesser NO20090256L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US83423506P	2006-07-28	2006-07-28
US89602607P	2007-03-21	2007-03-21
US11/782,704 US7671062B2 (en)	2006-07-28	2007-07-25	Modulators of chemokine receptor activity, crystalline forms and process
PCT/US2007/074438 WO2008014381A2 (en)	2006-07-28	2007-07-26	Modulators of chemokine receptor activity, crystalline forms and process

Publications (1)

Publication Number	Publication Date
NO20090256L true NO20090256L (no)	2009-02-25

Family

ID=38823540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090256A NO20090256L (no)	2006-07-28	2009-01-16	Modulatorer for kjemokine reseptoraktivitet, krystallinske former og prosesser

Country Status (29)

Country	Link
US (1)	US7671062B2 (de)
EP (2)	EP2184283A1 (de)
JP (1)	JP2009544758A (de)
KR (1)	KR20090035036A (de)
CN (1)	CN101511822A (de)
AR (1)	AR062114A1 (de)
AT (1)	ATE471928T1 (de)
AU (1)	AU2007279256A1 (de)
BR (1)	BRPI0715066A2 (de)
CA (1)	CA2659259A1 (de)
CL (3)	CL2007002194A1 (de)
CO (1)	CO6190527A2 (de)
CY (1)	CY1110785T1 (de)
DE (1)	DE602007007335D1 (de)
DK (1)	DK2049477T3 (de)
EA (1)	EA014960B1 (de)
ES (1)	ES2346591T3 (de)
HR (1)	HRP20100371T1 (de)
IL (1)	IL196518A0 (de)
MX (1)	MX2009000803A (de)
NO (1)	NO20090256L (de)
NZ (1)	NZ574656A (de)
PE (1)	PE20080838A1 (de)
PL (1)	PL2049477T3 (de)
PT (1)	PT2049477E (de)
SG (1)	SG158925A1 (de)
SI (1)	SI2049477T1 (de)
TW (1)	TW200823203A (de)
WO (1)	WO2008014381A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7687508B2 (en) *	2006-07-28	2010-03-30	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US8383812B2 (en) *	2009-10-13	2013-02-26	Bristol-Myers Squibb Company	N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
RU2726206C2 (ru)	2015-05-21	2020-07-09	Кемосентрикс, Инк.	Модуляторы ccr2
SMT202200088T1 (it) *	2017-07-20	2022-03-21	Bristol Myers Squibb Co	Procedimento per la preparazione di n-((1r,2s,sr)-5-(tert-butilammino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilammino)-2-ossopirrolidin-1-il)cicloesil)acetammide
EP3687525B1 (de)	2017-09-25	2025-10-29	ChemoCentryx, Inc.	Kombinationstherapie mit einem chemokinrezeptor-2 (ccr2)-antagonist und einem pd-1/pd-l1-inhibitor
CN112105353B (zh)	2018-01-08	2024-04-19	凯莫森特里克斯股份有限公司	Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
CN115494184B (zh) *	2022-05-09	2023-07-28	浙江海正药业股份有限公司	一种同时检测药物中异丙苯磺酸甲酯、异丙苯磺酸乙酯的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6383082A (ja)	1986-09-26	1988-04-13	Takeda Chem Ind Ltd	テトラヒドロフランカルボン酸誘導体の製造法
CA2084800A1 (en)	1991-12-16	1993-06-17	Joseph P. Vacca	Hiv protease inhibitors with an internal lactam ring
GB9515411D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	N-(4-substituted-benzyl)-2-aminolactam derivatives
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
UA51716C2 (uk)	1996-07-08	2002-12-16	Авентіс Фармасьютікалз Продактс Інк.	Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6054579A (en)	1997-06-26	2000-04-25	Leukosite, Inc.	Synthesis of substituted lactams
GB9716656D0 (en)	1997-08-07	1997-10-15	Zeneca Ltd	Chemical compounds
YU47600A (sh)	1998-01-27	2002-09-19	Aventis Pharmaceuticals Products Inc.	SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
EP1051397B1 (de)	1998-01-29	2008-12-31	Aventis Pharmaceuticals Inc.	Verfahren zur herstellung einer n-¬(aliphathisch oder aromatisch)carbonyl -2-aminoacetamid-verbindung und einer cyclischen verbindung
US6492553B1 (en)	1998-01-29	2002-12-10	Aventis Pharamaceuticals Inc.	Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB9803228D0 (en)	1998-02-17	1998-04-08	Zeneca Ltd	Chemical compounds
US6541208B1 (en)	1998-03-17	2003-04-01	University Of Maryland Biotechnology Institute	Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
WO2001017992A1 (en)	1999-09-09	2001-03-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6620823B2 (en)	2000-07-11	2003-09-16	Bristol-Myers Squibb Pharme Company	Lactam metalloprotease inhibitors
AR035773A1 (es)	2000-12-20	2004-07-14	Bristol Myers Squibb Pharma Co	Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina
CA2432908A1 (en)	2000-12-20	2002-06-27	Bristol-Myers Squibb Pharma Company	Diamines as modulators of chemokine receptor activity
AU2002249103A1 (en)	2001-03-29	2002-10-15	Topo Target Aps	Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
GB0114867D0 (en)	2001-06-18	2001-08-08	Merck Sharp & Dohme	Therapeutic agents
DE10135043A1 (de)	2001-07-11	2003-01-30	Bayer Cropscience Gmbh	Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren
EP1483241A4 (de)	2002-03-08	2006-12-13	Bristol Myers Squibb Co	Cyclische derivate als modulatoren der chemokinrezeptoraktivität
TW200307667A (en)	2002-05-06	2003-12-16	Bristol Myers Squibb Co	Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
AU2003263393A1 (en)	2002-09-04	2004-03-29	Glenmark Pharmaceuticals Limited	New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
TW200508224A (en)	2003-02-12	2005-03-01	Bristol Myers Squibb Co	Cyclic derivatives as modulators of chemokine receptor activity
WO2004071449A2 (en)	2003-02-12	2004-08-26	Bristol-Myers Squibb Company	Lactams as modulators of chemokine receptor activity
US7230133B2 (en)	2003-05-01	2007-06-12	Bristol-Myers Squibb Company	Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7291615B2 (en)	2003-05-01	2007-11-06	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
WO2004110376A2 (en)	2003-06-06	2004-12-23	Merck & Co., Inc.	Ccr-2 antagonists for treatment of neuropathic pain
US7378409B2 (en)	2003-08-21	2008-05-27	Bristol-Myers Squibb Company	Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7163937B2 (en)	2003-08-21	2007-01-16	Bristol-Myers Squibb Company	Cyclic derivatives as modulators of chemokine receptor activity
US7317019B2 (en)	2003-08-21	2008-01-08	Bristol Myers Squibb Co.	N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
US7863317B2 (en)	2003-08-21	2011-01-04	Bristol-Myers Squibb Company	Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
US20050043392A1 (en)	2003-08-21	2005-02-24	Carter Percy H.	Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
WO2006013427A2 (en)	2004-07-30	2006-02-09	Pfizer Products Inc.	Treatment of ccr2 mediated diseases or disorders
KR20070063562A (ko)	2004-09-28	2007-06-19	얀센 파마슈티카 엔.브이.	치환 디피페리딘 ｃｃｒ２ 길항제

2007
- 2007-07-25 US US11/782,704 patent/US7671062B2/en active Active
- 2007-07-26 EP EP10001344A patent/EP2184283A1/de not_active Withdrawn
- 2007-07-26 EP EP07799831A patent/EP2049477B1/de not_active Not-in-force
- 2007-07-26 AR ARP070103321A patent/AR062114A1/es not_active Application Discontinuation
- 2007-07-26 DE DE602007007335T patent/DE602007007335D1/de active Active
- 2007-07-26 CN CNA2007800327628A patent/CN101511822A/zh active Pending
- 2007-07-26 DK DK07799831.8T patent/DK2049477T3/da active
- 2007-07-26 AU AU2007279256A patent/AU2007279256A1/en not_active Abandoned
- 2007-07-26 SI SI200730305T patent/SI2049477T1/sl unknown
- 2007-07-26 TW TW096127306A patent/TW200823203A/zh unknown
- 2007-07-26 SG SG201000704-5A patent/SG158925A1/en unknown
- 2007-07-26 WO PCT/US2007/074438 patent/WO2008014381A2/en not_active Ceased
- 2007-07-26 BR BRPI0715066-0A patent/BRPI0715066A2/pt not_active IP Right Cessation
- 2007-07-26 PT PT07799831T patent/PT2049477E/pt unknown
- 2007-07-26 JP JP2009522956A patent/JP2009544758A/ja not_active Withdrawn
- 2007-07-26 KR KR1020097004327A patent/KR20090035036A/ko not_active Withdrawn
- 2007-07-26 CL CL200702194A patent/CL2007002194A1/es unknown
- 2007-07-26 CL CL200702195A patent/CL2007002195A1/es unknown
- 2007-07-26 CA CA002659259A patent/CA2659259A1/en not_active Abandoned
- 2007-07-26 EA EA200900244A patent/EA014960B1/ru not_active IP Right Cessation
- 2007-07-26 NZ NZ574656A patent/NZ574656A/en not_active IP Right Cessation
- 2007-07-26 HR HR20100371T patent/HRP20100371T1/hr unknown
- 2007-07-26 ES ES07799831T patent/ES2346591T3/es active Active
- 2007-07-26 CL CL200702196A patent/CL2007002196A1/es unknown
- 2007-07-26 AT AT07799831T patent/ATE471928T1/de active
- 2007-07-26 PE PE2007000968A patent/PE20080838A1/es not_active Application Discontinuation
- 2007-07-26 MX MX2009000803A patent/MX2009000803A/es active IP Right Grant
- 2007-07-26 PL PL07799831T patent/PL2049477T3/pl unknown
2009
- 2009-01-15 IL IL196518A patent/IL196518A0/en unknown
- 2009-01-16 NO NO20090256A patent/NO20090256L/no not_active Application Discontinuation
- 2009-01-27 CO CO09007271A patent/CO6190527A2/es not_active Application Discontinuation
2010
- 2010-09-22 CY CY20101100852T patent/CY1110785T1/el unknown

Also Published As

Publication number	Publication date
CA2659259A1 (en)	2008-01-31
TW200823203A (en)	2008-06-01
CL2007002196A1 (es)	2008-05-30
BRPI0715066A2 (pt)	2013-05-28
IL196518A0 (en)	2009-11-18
SG158925A1 (en)	2010-02-26
PT2049477E (pt)	2010-08-27
SI2049477T1 (sl)	2010-09-30
PL2049477T3 (pl)	2010-11-30
EA014960B1 (ru)	2011-04-29
WO2008014381A3 (en)	2008-12-31
CO6190527A2 (es)	2010-08-19
EP2049477A2 (de)	2009-04-22
DE602007007335D1 (de)	2010-08-05
HK1125931A1 (en)	2009-08-21
CN101511822A (zh)	2009-08-19
AU2007279256A1 (en)	2008-01-31
CY1110785T1 (el)	2015-06-10
US20080027083A1 (en)	2008-01-31
MX2009000803A (es)	2009-01-29
KR20090035036A (ko)	2009-04-08
WO2008014381A2 (en)	2008-01-31
JP2009544758A (ja)	2009-12-17
PE20080838A1 (es)	2008-06-14
ES2346591T3 (es)	2010-10-18
CL2007002195A1 (es)	2008-02-08
EA200900244A1 (ru)	2009-08-28
US7671062B2 (en)	2010-03-02
CL2007002194A1 (es)	2008-02-08
EP2184283A1 (de)	2010-05-12
AR062114A1 (es)	2008-10-15
NZ574656A (en)	2011-12-22
DK2049477T3 (da)	2010-10-25
ATE471928T1 (de)	2010-07-15
HRP20100371T1 (hr)	2010-08-31
EP2049477B1 (de)	2010-06-23

Legal Events

Date	Code	Title	Description
2013-03-11	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20090190L (no)	2009-01-29	Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate
WO2008014381A3 (en)	2008-12-31	Modulators of chemokine receptor activity, crystalline forms and process
MX2012003720A (es)	2012-04-30	N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
ATE469897T1 (de)	2010-06-15	Indazolcarbonsäureamidverbindungen
TW200745111A (en)	2007-12-16	New compounds
IL205697A0 (en)	2010-11-30	4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
DK1735278T3 (da)	2010-04-12	Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
NO20075574L (no)	2007-11-02	Krystallinsk form av en quinolinonkarboksamidforbindelse
NO20080033L (no)	2008-01-03	Kinolinderivater som NK3-antagonister
CY1109694T1 (el)	2014-08-13	Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
SE0401655D0 (sv)	2004-06-24	New compounds
TW200716607A (en)	2007-05-01	Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
TW200800984A (en)	2008-01-01	New compounds
WO2005123670A3 (en)	2006-02-09	Crystalline form of a substituted pyrrolidine compound
NO20063562L (no)	2006-11-06	Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
CY1115134T1 (el)	2016-12-14	N-((1r,2s,5r)-5-(t-boytyλamino)-2-((s)-3-(7-t-boytyλπypazoλo[1,5-a][1,3,5] tpiazin-4-υλαμινο)-2-οξοπυρρολιδιν-1-υλ)κυκλοεξυλ)ακεταμιδιο, διπλος ρυθμιστης δραστικοτητας υποδοχεων χημειοκινης, κρυσταλλικες μορφες και διεργασιες
MY143574A (en)	2011-05-31	Carbamate compounds as 5-ht4 receptor agonists
TH95794A (th)	2009-05-29	ตัวคุมฤทธิ์ตัวรับคีโมคีน รูปแบบผลึก และกระบวนการ
EA200702596A1 (ru)	2008-04-28	Кристаллическая форма производного малеата бензазепиния
TH97002B (th)	2009-07-24	ตัวคุมฤทธิ์ตัวรับคีโมคีน, รูปแบบผลึก และกระบวนการ